Diatec Monoclonals offers an excellent monoclonal antibody against human C5b-9, the Terminal Complement Complex (TCC). The antibody is produced in vitro by the aE11 hybridoma and purified with protein A to a purity more than 98%.
This antibody recognizes C5b-9, the terminal complement complex (TCC). TCC consist of C5b, C6, C7, C8 and C9 and contains neoantigens that are absent from the individual native components.
aE11 produces monoclonal antibodies against neoantigens of both membrane bound (MAC) and fluid phase (SC5b-9) complexes. This antibody is directed against a neoepitope exposed in C9 when incorporated into the terminal complement complex (TCC)
For research customers we ask you to contact our international distributor:
If you are in need of larger amounts of C5b-9 (>20 mg), please contact us direct.